Six (40%) studies involving 102,543 subjects assessed glucose dysregulation, of which two assessed hyperglycaemia as fasting blood glucose (FBG) >/= 5.6 mmol/L [28, 34], two considered diabetes diagnosis or prescriptions for medicines to lower blood glucose levels [35, 41], and the last two examined increases in FBG and/or insulin levels after treatment [30, 42]. The gene discussed is INS; the disease is diabetes mellitus.